MX2024011049A - Virus de la enfermedad de newcastle recombinantes y composiciones inmunogenicas para su uso en la prevencion de la covid-19. - Google Patents

Virus de la enfermedad de newcastle recombinantes y composiciones inmunogenicas para su uso en la prevencion de la covid-19.

Info

Publication number
MX2024011049A
MX2024011049A MX2024011049A MX2024011049A MX2024011049A MX 2024011049 A MX2024011049 A MX 2024011049A MX 2024011049 A MX2024011049 A MX 2024011049A MX 2024011049 A MX2024011049 A MX 2024011049A MX 2024011049 A MX2024011049 A MX 2024011049A
Authority
MX
Mexico
Prior art keywords
protein
immunogenic compositions
recombinant
newcastle disease
disease viruses
Prior art date
Application number
MX2024011049A
Other languages
English (en)
Spanish (es)
Inventor
Peter Palese
Florian Krammer
Adolfo Garcia-Sastre
Weina Sun
Dominguez Irene Gonzalez
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of MX2024011049A publication Critical patent/MX2024011049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024011049A 2022-03-10 2023-03-09 Virus de la enfermedad de newcastle recombinantes y composiciones inmunogenicas para su uso en la prevencion de la covid-19. MX2024011049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263318640P 2022-03-10 2022-03-10
PCT/US2023/064063 WO2023173032A2 (en) 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19

Publications (1)

Publication Number Publication Date
MX2024011049A true MX2024011049A (es) 2024-09-18

Family

ID=87936013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011049A MX2024011049A (es) 2022-03-10 2023-03-09 Virus de la enfermedad de newcastle recombinantes y composiciones inmunogenicas para su uso en la prevencion de la covid-19.

Country Status (11)

Country Link
US (1) US20250186578A1 (enExample)
EP (1) EP4489779A4 (enExample)
JP (1) JP2025509352A (enExample)
KR (1) KR20240161963A (enExample)
CN (1) CN119317446A (enExample)
AU (1) AU2023231285A1 (enExample)
CA (1) CA3245533A1 (enExample)
CL (1) CL2024002683A1 (enExample)
CO (1) CO2024012344A2 (enExample)
MX (1) MX2024011049A (enExample)
WO (1) WO2023173032A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007056A (es) * 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
WO2023056351A2 (en) * 2021-09-30 2023-04-06 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof

Also Published As

Publication number Publication date
EP4489779A2 (en) 2025-01-15
JP2025509352A (ja) 2025-04-11
CO2024012344A2 (es) 2024-12-30
KR20240161963A (ko) 2024-11-13
WO2023173032A3 (en) 2023-10-12
CN119317446A (zh) 2025-01-14
CA3245533A1 (en) 2023-09-14
EP4489779A4 (en) 2026-05-13
AU2023231285A1 (en) 2024-07-25
US20250186578A1 (en) 2025-06-12
CL2024002683A1 (es) 2025-01-03
WO2023173032A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MX2022013934A (es) Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
WO2023196759A3 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
WO2023056351A8 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
Kubo et al. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein
von Messling et al. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity
JP3961222B2 (ja) Ｐｒｒｓｖワクチン
ES2374131T3 (es) Flavivirus quiméricos avirulentos e inmunógenos.
ES2343371T3 (es) Procedimientos y composiciones para la vacunacion de animales con antigenos de vsrrp con una inmunogenicidad mejorada.
JP2004313196A (ja) コロナウイルスに対するワクチン接種用組成物および方法
WO2000002524A9 (en) Botulinum neurotoxin vaccine
EP3199178B1 (en) Live attenuated parvovirus
WO1993023422A1 (en) Compositions and methods for vaccination against coronaviruses
Linder et al. Structural elements in glycoprotein 70 from polytropic Friend mink cell focus-inducing virus and glycoprotein 71 from ecotropic Friend murine leukemia virus, as defined by disulfide-bonding pattern and limited proteolysis
US20130071429A1 (en) Bunyavirus vaccine
WO2023173032A3 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
US20250099568A1 (en) Chimeric Flavivirus Lyssavirus Vaccines
WO2006009011A1 (ja) コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
Lu et al. Construction and genetic analysis of dicistronic polioviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120
JP4856351B2 (ja) Ｂｖｄｖウイルス様粒子
ES2637629T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
WO2001055353A3 (en) Recombinant attenuation of prrsv
WO2023196945A3 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
KR101937792B1 (ko) 신규한 재조합 항원 단백질을 포함하는 구제역 백신 조성물
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
Yoo et al. Analysis of the S spike (peplomer) glycoprotein of bovine coronavirus synthesized in insect cells